

 Open access • Posted Content • DOI:10.1101/2020.06.16.20133116

## **Mental health during the COVID-19 pandemic in two longitudinal UK population cohorts — Source link**

Alex S. F. Kwong, Rebecca M. Pearson, Mark Adams, Kate Northstone ...+20 more authors

**Institutions:** University of Bristol, University of Edinburgh, Cardiff University, University College London ...+1 more institutions

**Published on:** 18 Jun 2020 - medRxiv (Cold Spring Harbor Laboratory Press)

**Topics:** Mental health, Anxiety, Health care, Longitudinal study and Anxiety disorder

Related papers:

- [Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population.](#)
- [Mental health before and during the COVID-19 pandemic in two longitudinal UK population cohorts.](#)
- [Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science.](#)
- [The psychological impact of quarantine and how to reduce it: rapid review of the evidence.](#)
- [A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/mental-health-during-the-covid-19-pandemic-in-two-19t5nfbyt2>

1 **Mental health during the COVID-19 pandemic in two longitudinal UK population cohorts**

2 Alex S. F. Kwong\* <sup>1,2,3</sup>, Rebecca, M. Pearson\* <sup>1,2</sup>, Mark, J. Adams <sup>3</sup>, Kate Northstone <sup>2</sup>, Kate Tilling  
3 <sup>1,2</sup>, Daniel Smith <sup>1,2</sup>, Chloe Fawns-Ritchie <sup>4</sup>, Helen Bould <sup>2,5</sup>, Naomi Warne <sup>2</sup>, Stan Zammit <sup>2,6</sup>, David  
4 Gunnell <sup>2,7</sup>, Paul Moran <sup>2,7,8</sup>, Nadia Micali <sup>9,10,11</sup>, Abraham Reichenberg <sup>12</sup>, Matthew Hickman <sup>2</sup>,  
5 Dheeraj Rai <sup>2,7,8</sup>, Simon Haworth <sup>1,2</sup>, Archie Campbell <sup>13,14</sup>, Drew Altschul <sup>13</sup>, Robin Flaig <sup>13,14</sup>,  
6 Andrew, M. McIntosh <sup>3</sup>, Deborah A. Lawlor <sup>1,2,7</sup>, David Porteous<sup>§</sup> <sup>13</sup>, Nicholas J. Timpson<sup>§</sup> <sup>1,2</sup>

7 <sup>1</sup>MRC Integrative Epidemiology Unit at the University of Bristol, United Kingdom

8 <sup>2</sup>Population Health Sciences, Bristol Medical School, University of Bristol, UK

9 <sup>3</sup>Division of Psychiatry, University of Edinburgh, UK

10 <sup>4</sup>Department of Psychology, University of Edinburgh, UK

11 <sup>5</sup>Gloucestershire Health and Care NHS Foundation Trust, Gloucester, UK

12 <sup>6</sup>MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and  
13 Clinical Neurosciences, Cardiff University, Cardiff, UK

14 <sup>7</sup>National Institute of Health Research (NIHR) Biomedical Research Centre, University of Bristol,  
15 Bristol, United Kingdom

16 <sup>8</sup>Avon and Wiltshire Mental Health Partnership National Health Service (NHS) Trust, Bristol, United  
17 Kingdom

18 <sup>9</sup>Great Ormond Street Institute of Child Health, University College London, London, UK

19 <sup>10</sup>Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

20 <sup>11</sup>Department of Paediatrics Gynaecology and Obstetrics, Faculty of Medicine, University of Geneva,  
21 Geneva, Switzerland

22 <sup>12</sup>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

23 <sup>13</sup>Centre for Genomic and Experimental Medicine, Institute of Genetics & Molecular Medicine,  
24 University of Edinburgh, Edinburgh, UK

25 <sup>14</sup>Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh,  
26 UK

27 \*Contributed equally to this work / <sup>§</sup>Contributed equally to this work

28 Corresponding Author: Alex S. F. Kwong, Population Health Sciences, Bristol Medical School,  
29 University of Bristol, United Kingdom.

30 E: Alex.Kwong@Bristol.ac.uk

31 Word count: 3917 (excluding abstract, tables, figures and references)

32 Keywords: COVID-19; pandemic; mental health; ALSPAC; Generation Scotland; depression;  
33 anxiety; wellbeing; longitudinal

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

34 **Summary**

35 **Background:** The impact of COVID-19 on mental health is unclear. Evidence from longitudinal  
36 studies with pre pandemic data are needed to address (1) how mental health has changed from pre-  
37 pandemic levels to during the COVID-19 pandemic and (2), whether there are groups at greater risk  
38 of poorer mental health during the pandemic?

39 **Methods:** We used data from COVID-19 surveys (completed through April/May 2020), nested within  
40 two large longitudinal population cohorts with harmonised measures of mental health: two  
41 generations of the Avon Longitudinal Study of Parents and Children (ALSPAC): the index generation  
42 ALSPAC-G1 (n= 2850, mean age 28) and the parent's generation ALSPAC-G0 (n= 3720, mean age  
43 = 59) and Generation Scotland: Scottish Family Health Study (GS, (n= 4233, mean age = 59), both  
44 with validated pre-pandemic measures of mental health and baseline factors. To answer question 1,  
45 we used ALSPAC-G1, which has identical mental health measures before and during the pandemic.  
46 Question 2 was addressed using both studies, using pre-pandemic and COVID-19 specific factors to  
47 explore associations with depression and anxiety in COVID-19.

48 **Findings:** In ALSPAC-G1 there was evidence that anxiety and lower wellbeing, but not depression,  
49 had increased in COVID-19 from pre-pandemic assessments. The percentage of individuals with  
50 probable anxiety disorder was almost double during COVID-19: 24% (95% CI 23%, 26%) compared  
51 to pre-pandemic levels (13%, 95% CI 12%, 14%), with clinically relevant effect sizes. In both  
52 ALSPAC and GS, depression and anxiety were greater in younger populations, women, those with  
53 pre-existing mental and physical health conditions, those living alone and in socio-economic  
54 adversity. We did not detect evidence for elevated risk in key workers or health care workers.

55 **Interpretation:** These results suggest increases in anxiety and lower wellbeing that may be related to  
56 the COVID-19 pandemic and/or its management, particularly in young people. This research  
57 highlights that specific groups may be disproportionately at risk of elevated levels of depression and  
58 anxiety during COVID-19 and supports recent calls for increasing funds for mental health services.

59 **Funding:** The UK Medical Research Council (MRC), the Wellcome Trust and University of Bristol.

60

## 61 **Introduction**

62 The coronavirus disease 2019 (COVID-19) pandemic has resulted in radical changes to societies  
63 globally. As the number of infected cases and deaths increased, many countries adopted public health  
64 measures including lockdown, social distancing and self-isolation. While such measures may be  
65 important for reducing transmission, they may also have a profound effect on mental health, [1-3]  
66 However, the extent to which mental health is affected by COVID-19 and its management, and who is  
67 at greatest risk, is unknown. Longitudinal studies with pre-pandemic data are vital for addressing this.

68 Although not directly comparable to COVID-19, evidence from previous viral outbreaks provide  
69 relevant information. The Severe Acute Respiratory Syndrome epidemic (SARS) resulted in public  
70 health mitigation measures in some countries and was associated with an increase (from pre-pandemic  
71 levels) in anxiety, depression, suicide and post-traumatic stress disorder during and beyond the  
72 conclusion of the outbreak for survivors of the virus, [4-6] and the unexposed public. [7, 8] Compared  
73 to SARS, the COVID-19 pandemic is greater in scale, resulting in more infections and deaths as well  
74 as more extreme mitigation methods. The consequences for mental health resulting from the COVID-  
75 19 pandemic could therefore be substantial. [1, 9] Unlike previous outbreaks, COVID-19 is  
76 widespread meaning the impact on global economy and health could be unprecedented.

77 Several rapid cross-sectional surveys during the COVID-19 pandemic have suggested a higher  
78 prevalence of anxiety, depression, [10, 11] and low wellbeing compared to historical estimates. [12,  
79 13] However, these studies lack pre-pandemic information in the same people, reporting symptoms  
80 during and before the pandemic. This precludes accurate assessment of changes in mental health.  
81 Furthermore, selection (due to mental health influencing who respond to surveys) and reporting bias  
82 (those who perceive depression and anxiety as higher or are more likely to report symptoms when  
83 they feel there is a ‘valid’ reason) could threaten the validity of results from cross-sectional surveys.  
84 [14] There is a need for data from longitudinal designs with well-characterized sampling frames and  
85 pre-pandemic data. Such studies can more accurately identify changing patterns of mental health and  
86 identify risk groups, informing development of interventions for those at heightened risk and aiding  
87 policy decisions regarding the immediate management of COVID-19, including plans for easing  
88 restrictions, as well as for the longer-term care for groups whose mental health may be particularly  
89 affected. [1, 9]

90 The COVID-19 pandemic is likely to exacerbate existing social and psychological inequalities. [15]  
91 Previous studies have identified several groups who may be at greater risk of poorer mental health  
92 during COVID-19, including younger people, women, healthcare workers and those with poorer  
93 financial or living circumstances. [10, 11, 13, 16] Parents with school-aged children, individuals at  
94 risk of physical and emotional abuse and those at greater physical risk of COVID-19 (older age, and

95 those with chronic conditions such as, asthma, obesity, diabetes) may also be at heightened risk of  
96 poorer mental health.

97 We used data from two large longitudinal cohort studies, both with rich pre-pandemic measures of  
98 mental health, to address (1) how has mental health changed from pre-pandemic levels to the COVID-  
99 19 pandemic and (2) are there groups at greater risk of poorer mental health during the pandemic? The  
100 first of these is important for exploring the impact of COVID-19 and its management on mental health  
101 and potential increases in poor mental health long-term. The second is important for targeting of  
102 mental health care needs now and during any subsequent waves and for identifying groups who might  
103 benefit from long-term monitoring after the pandemic.

## 104 **Methods**

### 105 **Samples**

106 We selected two comparable cohort studies to allow replication in different regions of the UK, but  
107 with similar timings of mental health measures before and during the COVID-19 pandemic.

108 The Avon Longitudinal Study of Parents and Children (ALSPAC) is an ongoing longitudinal  
109 population-based study that recruited pregnant women residing in Avon in the south-west of England  
110 with expected delivery dates between 1<sup>st</sup> April 1991 and 31<sup>st</sup> December 1992. [17, 18] The cohort  
111 consists of 13,761 mothers and their partners (hereafter referred to as ALSPAC-G0), and their 14,901  
112 children (ALSPAC-G1). [19] The study website contains details of all data available through a fully  
113 searchable data dictionary (<http://www.bristol.ac.uk/alspac/researchers/our-data/>). Ethical approval  
114 for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research  
115 Ethics Committees.

116 Generation Scotland: Scottish Family Health Study (GS) is a family longitudinal study of 24,084  
117 individuals recruited across Scotland between 2006 and 2011.[20] Participants were recruited into the  
118 study if they were aged 18 or over. Participants of GS have been followed up longitudinally, [21] and  
119 further details can be found on the study website (<http://www.generationscotland.org>). Ethical  
120 approval for the study was approved by NHS Tayside Committee on Medical Research Ethics  
121 (reference 05/S1401/89).

122 This study uses data from 3720 ALSPAC-G0 and 2973 ALSPAC-G1 who completed an online  
123 questionnaire about the impact and consequences of the COVID-19 pandemic between 9<sup>th</sup> April and  
124 14<sup>th</sup> May 2020 (see, appendix figure 1 and figure 2) [22]. In GS, data were from 4,233 individuals  
125 who completed a similar online COVID-19 questionnaire between 17<sup>th</sup> April and 17<sup>th</sup> May 2020 (see,  
126 appendix figure 3). Lockdown was announced in the UK on the 24<sup>th</sup> March.

### 127 **COVID-19 pandemic measures of mental health**

128 The measures used in the COVID-19 survey examine symptoms in the preceding 2 weeks, thus  
129 represent mental health in the immediate period following lockdown. Depressive symptoms in  
130 ALSPAC were measured using the Short Mood and Feelings Questionnaire (SMFQ), [23] a 13-item  
131 instrument examining depressive mood. Scores range between 0-26 with higher scores indicting  
132 higher depressive symptoms. In GS, depressive symptoms were measured using the Patient Health  
133 Questionnaire (PHQ-9), [24] a 9-item instrument which monitors depressive symptoms. Scores range  
134 between 0-27 with higher scores indicating worse depressive symptoms. Anxiety symptoms in  
135 ALSPAC and GS was measured using the same instrument, the Generalised Anxiety Disorder  
136 Assessment (GAD-7), [25] a 7-item instrument which measures the presence of generalised anxiety

137 disorder symptoms. Scores range between 0-21 with higher scores indicting higher anxiety symptoms.  
138 Mental wellbeing in ALSPAC and GS was also measured using the same instrument, the Short  
139 Warwick-Edinburgh Mental Wellbeing Scale (SWEMWBS), [26] a 7-item instrument which  
140 measures positive mental wellbeing. Scores range between 7-35, with higher scores indicating better  
141 mental wellbeing. These measures have recommended cut-offs for examining the proportion of  
142 individuals with probable depression ( $\geq 11$  on SMFQ and  $\geq 10$  on PHQ-9), generalised anxiety  
143 disorder ( $\geq 10$  on GAD-7) and poor mental wellbeing ( $\leq 17$  on SWEMWBS), with good sensitivity and  
144 specificity for identifying clinical disorder using validated interviews and instruments and widely  
145 used in primary care and clinical trials (see appendix methods). Herein we refer to depressive  
146 symptoms as depression and anxiety symptoms as anxiety.

### 147 **Baseline (pre-pandemic) measures of mental health and factors**

148 Baseline depression and anxiety were assessed in ALSPAC and GS prior to the COVID-19 pandemic.  
149 In ALSPAC-G1, baseline mental wellbeing was also assessed. These measures are described in Table  
150 1, alongside information on the baseline factors that may predict poorer mental health in COVID-19.  
151 We refer to these as factors to make it clear that we are not assuming they are causal but could be  
152 useful for identifying vulnerable groups. The factors we explored included demographic and social  
153 information such as sex, age, educational background, financial circumstances, deprivation status,  
154 victimisation and being a parent with school-aged children. Additional factors included pre-existing  
155 mental health conditions, substance misuse, genetic risk for depression, cognitive styles, personality  
156 traits and difficulties accessing mental health information. Due to differences in data collection,  
157 several factors are only assessed in either ALSPAC or GS. We also examined associations with  
158 several COVID-19 specific factors that may be valuable predictors of adverse mental health,  
159 including obesity, asthma, infection status, isolation status, living alone, access to a garden, health-  
160 care worker and key worker status. Detailed information regarding the descriptions and timing of  
161 these measures including availability and how measures were harmonised, are given in the appendix  
162 method section.

### 163 **Statistical analysis**

164 Analysis was conducted in StataSE (version 15). Initially, we described the prevalence of mental  
165 health outcomes during the COVID-19 pandemic in all cohorts. To answer our first research question,  
166 we used ALSPAC-G1 to examine how mental health changed from baseline (pre-pandemic) to  
167 COVID-19 levels. This analysis was only possible in ALSPAC-G1 who had identical mental health  
168 measures at baseline and during COVID-19.

169 To answer our second research question, we examined associations between factors (both baseline  
170 measures and those specific to and measured during the pandemic) and COVID-19 depression and

171 anxiety. Analysis was conducted separately for all cohorts, adjusting for sex, age and the date they  
172 completed the COVID-19 questionnaire (to account for heterogeneity in response times). In  
173 ALSPAC-G0 and GS, we used alternative measures capturing the same construct to account for pre-  
174 existing depression and anxiety (the EPDS in ALSPAC-G and the GHQ-28 in GS). Wellbeing was  
175 not assessed at baseline in ALSPAC-G1 or GS, therefore we restrict this analysis to depression and  
176 anxiety only. The results for question two can be interpreted as identifying factors associated with  
177 depression and anxiety, that are not driven by past symptoms of either disorder (as they are adjusted  
178 for in the model). Continuous COVID-19 and baseline depression and anxiety were standardised to  
179 create Z scores allowing comparison of effect sizes across outcomes and cohorts.

#### 180 *Missing data*

181 Our eligible samples were defined as those who completed at least one mental health measure during  
182 the COVID-19 surveys: ALSPAC-G0 n= 3579, ALSPAC-G1 n= 2872 and GS n =4208 (appendix  
183 figures 1-3, appendix table 1). We imputed incomplete baseline depression, anxiety and factors using  
184 earlier or concurrent information up to the eligible samples, using multiple imputation by chained  
185 equations to generate 50 imputed datasets. [27] Full information on the proportion of missing baseline  
186 data in each cohort are given in the appendix table 2-4, the majority (>80%) of participants had more  
187 than 50% of complete baseline data (i.e., all factors and baseline mental health) with less than 1%  
188 only having information on only 1 or 2 baseline variables. Analyses on multiple imputed datasets uses  
189 rich pre-pandemic data available to plausibly meet the assumption that data are missing at random,  
190 i.e., conditional on observed information. Whereas, complete case analyses assume that missingness is  
191 not related to the outcome conditional on the exposure and any covariables. Given that we have  
192 demonstrated that the missing baseline data was associated with lower education and sex (appendix  
193 table 1) it is likely that the complete case sample is biased and thus we primarily present imputed  
194 estimates which also increase power. Details regarding imputation are fully described in the appendix.

#### 195 *Sensitivity analyses*

196 In sensitivity analysis, we also examined depression and anxiety using the 'proportion-above-  
197 threshold' in logistic regressions rather than continuous scores as outcomes, analysed varying ages for  
198 baseline measures and estimated 'counterfactual' trajectories for the mental health measures to  
199 highlight differences in the observed compared to predicted trajectories.

#### 200 **Role of the funding source**

201 The funders of the study had no role in the study design, data collection, data analysis, data  
202 interpretation, or writing of this manuscript. The corresponding author had full access to the data in  
203 the study and had final responsibility for the decision to submit for publication.

204



## 205 **Results**

206 Data on COVID-19 mental health outcomes in ALSPAC-G0 were available for 3579 people (mean  
207 age: 58.67 years, SD: 4.82), for ALSPAC-G1, 2872 people (mean age: 27.61 years, SD: 0.54 ) and GS  
208 4208 people (mean age: 59.24 years, SD: 12.03), see appendix figures 1-3, appendix table 1.

### 209 *Prevalence of mental health outcomes during COVID-19*

210 The prevalence of probable depression decreased with age in ALSPAC and GS. Similar results were  
211 observed for probable anxiety and low wellbeing (Figure 1).

### 212 *Change in mental health in ALSPAC-G1*

213 The percentage of individuals with probable depression was lower, 18.14 % (16.76, 19.61), in  
214 COVID, compared to 24.35 % (23.04, 25.70) at the most recent baseline. The percentage of people  
215 with probable anxiety disorder was almost double during COVID-19 :24% (95% CI 23% ,26%)  
216 compared to pre-pandemic levels (13%, 95% CI 12 %, 14%) and for lower wellbeing :13, (95% CI 12  
217 to 14%%) compared to 8% (95% CI 7 to 9%) (Figure 2, appendix table 5 and 6). When examining  
218 continuous measures of mental health, there was a mean difference in SMFQ score of -0.60 (95% CI:  
219 -0.84, -0.37), 1.36 (95% CI: 1.10, 1.61) for GAD-7 and 2.45 (95% CI 2.25 to 2.65) for SWEMWBS,  
220 when comparing the most recent baseline to COVID-19. To give a summary of magnitude, these  
221 estimates represent a 0.11, 0.26 and 0.51 standardised effect difference respectively (appendix table  
222 7). Item level differences for each measure are shown in figure 3.

### 223 *Factors related to depression and anxiety during COVID-19*

224 Table 2 and figures 4 and 5 show the associations between baseline and COVID-19 specific factors  
225 and depression and anxiety, with adjustment for baseline depression and anxiety symptoms (measured  
226 on a continuous scale in standard deviation units for ease of comparison between cohorts and  
227 outcomes).

228 A reported or suspected COVID-19 infection was associated with higher depression and anxiety in  
229 ALSPAC-G0, but only higher depression in GS with no associations observed in ALSPAC-G1.

230 Living alone during the pandemic was associated with higher depression, but not with higher anxiety  
231 in ALSPAC and GS. No access to a garden was associated with higher depression in all cohorts and  
232 greater anxiety in GS. ALSPAC-G0 and ALSPAC-G1 participants who reported that they had self-  
233 isolated had higher depression and anxiety, but it was not possible to test this in GS. Key workers (of  
234 any kind) and health care workers were not associated with higher depression or anxiety. There was  
235 an association between being a key worker and having lower depression in ALSPAC-G1, but this was  
236 not replicated in ALSPAC-G1 or GS.

237 For pre-pandemic factors, focusing on replicated results (those showing consistent associations in at  
238 least two cohorts), we found evidence for higher depression and anxiety in women, those with  
239 financial problems, lower educational backgrounds, lower income, living in a more deprived area,  
240 those with obesity. A positive association of being a parent of a young child with higher anxiety in  
241 ALSPAC-G1 did not replicate in GS and was not associated with depression in either cohort.  
242 Reporting an emotionally abusive partner was only available in ALSPAC-G0 but was positively  
243 associated with both greater depression and anxiety. Asthma had positive associations with higher  
244 anxiety in ALSPAC-G1 and GS but was not associated with depression in both cohorts.

245 There were strong and replicated associations between several pre-existing mental health problems  
246 and higher depression and anxiety, including a history of major depression disorder, psychosis-like  
247 symptoms, negative cognition, neuroticism, and a history of self-harm. The depression polygenic risk  
248 score was also positively associated with depression and anxiety in ALSPAC-G0 and GS (though not  
249 in ALSPAC-G1).

250 Depression and anxiety were higher in ALSPAC-G1 in those who reported generalised anxiety  
251 disorder, OCD traits, disordered eating, autistic traits, and difficulty accessing mental health services,  
252 but these outcomes were not available in ALSPAC-G1 or GS and so could not be replicated.  
253 Personality disorder traits were associated only with higher anxiety in G1 but both anxiety and  
254 depression ALSPAC-G0. A history of alcohol abuse was associated with increased depression in  
255 ALSAPC-G1 and anxiety in both ALSAPC-G0 and ALSPAC-G1, but not replicated in GS. By  
256 contrast smoking was associated with increased depression and anxiety in both ALSPAC-G0 and GS  
257 but not ALSPAC-G1.

258 Results were similar using complete case analysis (appendix table 8), adjusting for educational  
259 background with imputation (appendix table 9), using different timings of baseline depression and  
260 anxiety (appendix tables 10 and 11) and examining binary outcomes (appendix table 12).

## 261 Discussion

262 We report a population-based longitudinal study to track changes in depression and anxiety from  
263 before to during the COVID-19 pandemic, providing potentially important new information for policy  
264 planning. Although we found no clear evidence that depression has changed during COVID-19 from  
265 pre-pandemic waves in ALSPAC-G1, there was strong observational evidence that anxiety and lower  
266 wellbeing were higher during COVID-19 compared to pre-pandemic levels. Approximately twice as  
267 many young adults experienced probable anxiety disorder and low wellbeing during the pandemic  
268 compared to previous waves. The mean rises of 0.26 SD in GAD-7 scores and 0.51 SD in  
269 SWEMWBS represent effect sizes that are clinically important and are seen in those following  
270 treatment (in the opposite direction). [28, 29] While mental health is dynamic and changes over time,  
271 evidence suggests that mood disorders tend to stabilise throughout adulthood, so the rise in anxiety  
272 and reduction in wellbeing in ALSPAC-G1 goes against what we would expect in the absence of  
273 COVID-19. [30] Our trajectory analyses (see appendix figure 4) suggested that higher anxiety and  
274 lower wellbeing deviated from expected levels, but that depression was in line with expectations in  
275 comparison to previous waves.

276 The uncertainty and sudden change to everyday life, as well as concerns over health, may explain why  
277 anxiety, rather than depression, has initially risen. The apparent rise in younger ages may reflect the  
278 impact of mitigation measures (i.e., lockdown and social distancing) rather than a risk of COVID-19  
279 infection (which may be higher in older populations). Furthermore, depression usually relates to  
280 feelings of loss, whilst anxiety relates to threat, as the majority of participants may not yet have lost  
281 anything (e.g., death of loved one, loss of job) this may also explain why depression has currently  
282 remained stable. There is also evidence that anxiety changes more rapidly than depression following  
283 treatment. [28]. What separates this pandemic from historical outbreaks, is the global impact. This,  
284 alongside the community spirit, may have been protective against the self-blame and guilt intrinsic to  
285 depression. [31] Indeed, depression items that were lower in the pandemic, as compared to previous  
286 waves, related to feelings of self-blame. As social inequalities become apparent and threat of loss  
287 becomes actual loss, this may change. The current survey was in UK spring, whereas previous  
288 ALSPAC-G1 waves were predominantly completed in winter. Seasonal trends suggest that depression  
289 and anxiety scores are approximately 1-2 points (0.1 SD) lower and 5% less of individuals are above  
290 thresholds in spring than winter, [32] which may explain lower depression scores.

291 Irrespective of the overall change in depression and anxiety in each cohort, several sociodemographic,  
292 psychological, physical and COVID-19 factors were associated with greater depression and anxiety  
293 during COVID-19. A reported or suspected COVID-19 infection was a factor for higher depression  
294 and anxiety in ALSPAC-G0 and GS, possibly reflecting the high perceived risk to physical health in  
295 older ages. This supports previous research, [2] but must be interpreted with caution because COVID-

296 19 status here largely includes participants' perception that they have COVID-19. Therefore, it maybe  
297 that those with pre-existing depression and anxiety are more likely to perceive that their symptoms are  
298 COVID-19 rather than other conditions. There was consistent evidence in participants from ALSPAC  
299 and GS that health risk groups linked to COVID-19, such as those with obesity and to some extent  
300 asthma, had higher depression and anxiety during COVID-19, potentially reflecting concerns  
301 regarding perceived risk of infection or the impact of more stringent social distancing. There was no  
302 evidence that key workers or health workers were at greater risk of depression or anxiety, suggesting  
303 these groups are not yet experiencing difficulties. This may reflect the heterogenous group of  
304 occupations included in this group, but whilst we observed no initial change in these groups, as the  
305 situation continues, frontline health care workers may become at risk of PTSD.

306 Those reporting self-isolation were at higher risk of both anxiety and depression but living alone was  
307 consistently associated with greater depression only. The manifestation of depression rather than  
308 anxiety for those living alone may relate to loneliness which is amplified with physical contact  
309 restricted to within households, again reflecting depression being related to absence and loss rather  
310 than threat. Whereas, self-isolation (which in this context is related to having symptoms) may be  
311 linked to anxiety through associated threat of the virus. Parents of young children were more anxious  
312 in ALSPAC, which may reflect stress related to the sudden change in childcare provision. Financial  
313 problems, lower income and deprivation were associated with greater risk of depression and anxiety  
314 in ALSPAC-G0 and GS. Financial problems, but not lower income, was also associated with higher  
315 depression and anxiety in ALSPAC-G1. Whilst these cohorts may have different populations,  
316 replication of financial concerns highlights the potential importance of global policies to mitigate the  
317 sudden social-economic impact and ensure emergency financial measures are accessible. [16]

318 As expected, individuals with a history of poorer mental health across multiple domains were at  
319 greater risk of higher depressive and anxiety during COVID-19, supporting concerns raised at the  
320 beginning of this pandemic. [1, 33, 34] Personality traits such as neuroticism and negative thinking  
321 patterns are strong factors for higher depression and anxiety during COVID-19 and are modifiable  
322 with interventions which could benefit those at risk now or in future outbreaks, even if delivered  
323 remotely. [35] ALSPAC-G0 and GS participants with genetic risk for depression were associated with  
324 poorer mental health, yet these effects were much weaker in ALSPAC-G1.

325 There are several limitations to this work. Firstly, as the pandemic is a universal exposure, it is  
326 difficult to attribute factors to the impact of the COVID-19 pandemic specifically, with many factors  
327 likely to show an association with later depression and anxiety at any time. [31] However, using  
328 longitudinal data and methods, we were able to demonstrate that anxiety and lower wellbeing were  
329 worse during COVID-19 than expected, given the comparison between baseline and pandemic  
330 assessments, so it is unlikely these effects are not related to COVID-19. Secondly, there were

331 heterogeneous measurements of mental health in COVID-19 specific surveys and baseline, as well as  
332 differences in the length of follow up across cohorts. This poses a challenge in inferring strong  
333 conclusions on change and specificity of findings to generations or cohorts. However, several  
334 sensitivity analyses in both cohorts and exploring different baselines reached similar conclusions.  
335 Thirdly, we were only able to assess change over the pandemic in ALSPAC-G1. Therefore, our  
336 inferences may only be relevant to young adult populations. However, given the replication between  
337 younger ages and higher rates of depression and anxiety, it is likely these effects will be observed in  
338 other studies. Fourthly, although we were able to use existing data such as educational background to  
339 predict baseline missingness and use such variables in imputation models, we did not impute further  
340 than the sample with complete COVID-19 survey data, given that data was unique. Thus, there may  
341 be issues with generalisability as respondents were more likely to be female and from higher  
342 educational backgrounds than previous ALSPAC and GS surveys. Furthermore, the meaning and  
343 interpretation of depression, anxiety and wellbeing may vary during pandemics, for example, some  
344 level of tension and fear may be adaptive and appropriate. However, our item level analysis revealed  
345 that all anxiety and mental wellbeing items were worse during COVID-19, implying a global decrease  
346 in these aspects of mood, not just for specific components. Finally, we compared multiple factors and  
347 therefore some statistical associations may have occurred as a result of chance. However, for most  
348 factors, there was evidence for replication of findings across multiple cohorts, suggesting that  
349 ‘chance’ findings are less likely.

350 Future work is needed to understand the mechanisms and complex interplay between baseline and  
351 COVID-19 specific factors and mental health during the COVID-19 pandemic. Future research should  
352 also consider how changes in anxiety might influence public behaviour through contact patterns and  
353 compliance with policies. Depression and anxiety, along with associated impairment should continue  
354 to be carefully monitored to forecast the long-term impact of this crisis. This can help ensure that  
355 future policies consider optimal preservation of both physical and mental health.

356 **Contributors**

357 ASFK, RMP, MJA, KN, KT, AMM, DAL, DP and NJT contributed to the conception and design of  
358 the study. ASFK, RMP, MJA, KN, AC, SH, CFR, DA, RF, DS, DP and NJT contributed to the  
359 organisation of the conduct of the study. ASFK carried out the study (including acquisition of data).  
360 ASFK and MJA analysed the data. ASFK and RMP drafted the initial output. All authors contributed  
361 to the interpretation of data. All authors have read and approved the final version of the manuscript.  
362 ASFK will serve as guarantor for the contents of the paper.

363 **Declaration of interests**

364 We declare no competing interests.

365 **Data availability**

366 ALSPAC data is available to researchers through an online proposal system. Information regarding  
367 access can be found on the ALSPAC website ([http://www.bristol.ac.uk/media-](http://www.bristol.ac.uk/media-library/sites/alspac/documents/researchers/data-access/ALSPAC_Access_Policy.pdf)  
368 [library/sites/alspac/documents/researchers/data-access/ALSPAC\\_Access\\_Policy.pdf](http://www.bristol.ac.uk/media-library/sites/alspac/documents/researchers/data-access/ALSPAC_Access_Policy.pdf)).

369 GS:SFHS data is available to researchers on application to the Generation Scotland Access  
370 Committee ([access@generationscotland.org](mailto:access@generationscotland.org)). The managed access process ensures that approval is  
371 granted only to research which comes under the terms of participant consent.

372 **Acknowledgments**

373 The UK Medical Research Council and Wellcome (Grant Ref: 217065/Z/19/Z) and the University of  
374 Bristol provide core support for ALSPAC. A comprehensive list of grants funding is available on the  
375 ALSPAC website (<http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf>).  
376 We are extremely grateful to all the families who took part in this study, the midwives for their help in  
377 recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory  
378 technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. Part  
379 of this data was collected using REDCap, see the REDCap website for details  
380 <https://projectredcap.org/resources/citations/>). ASFK, RMP, KT, DS, SH, DAL, NJT work in or are  
381 affiliated to the MRC Integrative Epidemiology Unit which is funded by the University of Bristol and  
382 UK Medical Research Council (MC\_UU\_00011/3 and MC\_UU\_00011/6). European Research  
383 Council under the European Union's Seventh Framework Programme, and grants 758813, MHINT  
384 and 669545 from the European Research Council Grant Agreements. This work was supported by  
385 Wellcome through the Wellcome Longitudinal Population Studies COVID-19 Secretariat and  
386 Steering Group (UK LPS COVID co-ordination, Grant Ref: 221574/Z/20/Z). This work was also  
387 supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation  
388 Trust and the University of Bristol. Generation Scotland received core support from the Chief

389 Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding  
390 Council [HR03006], and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping  
391 of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Wellcome Trust  
392 Clinical Research Facility, University of Edinburgh, Scotland, funded by the MRC and Wellcome  
393 Trust [104036/Z/14/Z]. This work has made use of the resources provided by the Edinburgh Compute  
394 and Data Facility (ECDF) (<http://www.ecdf.ed.ac.uk/>). NJT is a Wellcome Trust Investigator  
395 (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT  
396 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-  
397 1215-2001), the MRC Integrative Epidemiology Unit (MC\_UU\_00011) and works within the CRUK  
398 Integrative Cancer Epidemiology Programme (C18281/A19169). DG, PM, SZ and DR are supported  
399 by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust.  
400 None of the named funders influenced the study design, data collection, analyses or interpretation of  
401 results. The views expressed in this paper are those of the authors and not necessarily of any of the  
402 funders, the National Health Service or the Department of Health.

403 **References**

- 404 1. Holmes, E.A., et al., *Multidisciplinary research priorities for the COVID-19 pandemic: a call for*  
405 *action for mental health science*. The Lancet Psychiatry, 2020.
- 406 2. Rogers, J.P., et al., *Psychiatric and neuropsychiatric presentations associated with severe*  
407 *coronavirus infections: a systematic review and meta-analysis with comparison to the*  
408 *COVID-19 pandemic*. The Lancet Psychiatry, 2020.
- 409 3. Brooks, S.K., et al., *The psychological impact of quarantine and how to reduce it: rapid review*  
410 *of the evidence*. The Lancet, 2020. **395**(10227): p. 912-920.
- 411 4. Lam, M.H., et al., *Mental Morbidities and Chronic Fatigue in Severe Acute Respiratory*  
412 *Syndrome Survivors: Long-term Follow-up*. Arch Intern Med, 2009. **169**(22): p. 2142-2147.
- 413 5. Cheung, Y.T., P.H. Chau, and P.S. Yip, *A revisit on older adults suicides and Severe Acute*  
414 *Respiratory Syndrome (SARS) epidemic in Hong Kong*. Int J Geriatr Psychiatry, 2008. **23**(12):  
415 p. 1231-8.
- 416 6. Mak, I.W., et al., *Long-term psychiatric morbidities among SARS survivors*. Gen Hosp  
417 Psychiatry, 2009. **31**(4): p. 318-26.
- 418 7. Lau, J.T.F., et al., *Avoidance behaviors and negative psychological responses in the general*  
419 *population in the initial stage of the H1N1 pandemic in Hong Kong*. BMC Infectious Diseases,  
420 2010. **10**(139).
- 421 8. Tsang, H.W.H., R.J. Scudds, and E.Y.L. Chan, *Psychosocial Impact of SARS*. Emerging  
422 Infectious Diseases, 2004. **10**(7).
- 423 9. Xiang, Y.-T., et al., *Timely mental health care for the 2019 novel coronavirus outbreak is*  
424 *urgently needed*. The Lancet Psychiatry, 2020. **7**(3): p. 228-229.
- 425 10. Qiu, J., et al., *A nationwide survey of psychological distress among Chinese people in the*  
426 *COVID-19 epidemic: implications and policy recommendations*. Gen Psychiatr, 2020. **33**(2): p.  
427 e100213.
- 428 11. Lai, J., et al., *Factors Associated With Mental Health Outcomes Among Health Care Workers*  
429 *Exposed to Coronavirus Disease 2019*. JAMA Netw Open, 2020. **3**(3): p. e203976.
- 430 12. Office for National Statistics. *Personal and economic well-being in Great Britain: May 2020*.  
431 2020 4th May 2020 [cited 2020 16th May]; Available from:  
432 [https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/bulletins/personaland](https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/bulletins/personalandeconomicwellbeingintheuk/may2020)  
433 [economicwellbeingintheuk/may2020](https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/bulletins/personalandeconomicwellbeingintheuk/may2020).
- 434 13. Fancourt, D., et al. *COVID-19 Social Study - Results Release 10*. 2020 30th May 2020].
- 435 14. Pierce, M., et al., *Says who? The significance of sampling in mental health surveys during*  
436 *COVID-19*. The Lancet Psychiatry, 2020.
- 437 15. Gunnell, D., et al., *Suicide risk and prevention during the COVID-19 pandemic*. The Lancet  
438 Psychiatry, 2020.
- 439 16. Wright, L., A. Steptoe, and D. Fancourt, *How are adversities during COVID-19 affecting*  
440 *mental health? Differential associations for worries and experiences and implications for*  
441 *policy*. medRxiv, 2020.
- 442 17. Boyd, A., et al., *Cohort Profile: the 'children of the 90s'--the index offspring of the Avon*  
443 *Longitudinal Study of Parents and Children*. Int J Epidemiol, 2013. **42**(1): p. 111-27.
- 444 18. Fraser, A., et al., *Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC*  
445 *mothers cohort*. Int J Epidemiol, 2013. **42**(1): p. 97-110.
- 446 19. Northstone, K., et al., *The Avon Longitudinal Study of Parents and Children (ALSPAC): an*  
447 *update on the enrolled sample of index children in 2019*. Wellcome Open Res, 2019. **4**: p. 51.
- 448 20. Smith, B.H., et al., *Cohort Profile: Generation Scotland: Scottish Family Health Study*  
449 *(GS:SFHS). The study, its participants and their potential for genetic research on health and*  
450 *illness*. Int J Epidemiol, 2013. **42**(3): p. 689-700.



- 451 21. Navrady, L.B., et al., *Cohort Profile: Stratifying Resilience and Depression Longitudinally*  
452 *(STRADL): a questionnaire follow-up of Generation Scotland: Scottish Family Health Study*  
453 *(GS:SFHS)*. *Int J Epidemiol*, 2018. **47**(1): p. 13-14g.
- 454 22. Northstone, K., et al., *The Avon Longitudinal Study of Parents and Children - A resource for*  
455 *COVID-19 research: Questionnaire data capture April-May 2020*. Wellcome Open Research,  
456 2020. **5**.
- 457 23. Angold, A., et al., *Development of a short questionnaire for use in epidemiological studies of*  
458 *depression in children and adolescents*. *International Journal of Methods in Psychiatric*  
459 *Research*, 1995. **5**(4): p. 237-249.
- 460 24. Kroenke, K., R.L. Spitzer, and J.B. Williams, *The PHQ-9: Validity of a Brief Depression Severity*  
461 *Measure*. *J Gen Intern Med*, 2001. **16**(9): p. 606-613.
- 462 25. Spitzer, R.L., et al., *A Brief Measure for Assessing Generalized Anxiety Disorder*. *Arch Intern*  
463 *Med*, 2006. **166**: p. 1092-1097.
- 464 26. Stewart-Brown, S., et al., *Internal construct validity of the Warwick-Edinburgh Mental Well-*  
465 *being Scale (WEMWBS): a Rasch analysis using data from the Scottish Health Education*  
466 *Population Survey*. *Health Qual Life Outcomes*, 2009. **7**: p. 15.
- 467 27. Royston, P. and I.R. White, *Multiple Imputation by Chained Equations (MICE):*  
468 *Implementation in Stata*. *Journal of Statistical Software*, 2011. **45**(4).
- 469 28. Lewis, G., et al., *The clinical effectiveness of sertraline in primary care and the role of*  
470 *depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled*  
471 *randomised trial*. *The Lancet Psychiatry*, 2019. **6**(11): p. 903-914.
- 472 29. Carpenter, J.K., et al., *Cognitive behavioral therapy for anxiety and related disorders: A meta-*  
473 *analysis of randomized placebo-controlled trials*. *Depress Anxiety*, 2018. **35**(6): p. 502-514.
- 474 30. Sutin, A.R., et al., *The trajectory of depressive symptoms across the adult life span*. *JAMA*  
475 *Psychiatry*, 2013. **70**(8): p. 803-11.
- 476 31. Malhi, G.S. and J.J. Mann, *Depression*. *Lancet*, 2018. **392**: p. 2299-2312.
- 477 32. Lukmanji, A., et al., *Seasonal variation in symptoms of depression: A Canadian population*  
478 *based study*. *J Affect Disord*, 2019. **255**: p. 142-149.
- 479 33. Druss, B.G., *Addressing the COVID-19 Pandemic in Populations With Serious Mental Illness*.  
480 *JAMA Psychiatry*, 2020.
- 481 34. Yao, H., J.-H. Chen, and Y.-F. Xu, *Patients with mental health disorders in the COVID-19*  
482 *epidemic*. *The Lancet Psychiatry*, 2020. **7**(4).
- 483 35. Shore, J.H., C.D. Schneck, and M.C. Mishkind, *Telepsychiatry and the Coronavirus Disease*  
484 *2019 Pandemic-Current and Future Outcomes of the Rapid Virtualization of Psychiatric Care*.  
485 *JAMA Psychiatry*, 2020.

486

## Tables and figures

	ALSPAC-G0	ALSPAC-G1	Generation Scotland
	Measure	Measure	Measure
<b><u>Sociodemographic factors</u></b>			
Sex	Questionnaire item	Questionnaire item	Questionnaire item
Age	Questionnaire item	Questionnaire item	Questionnaire item
Educational background	Questionnaire item	Questionnaire item	Questionnaire item
Income	Questionnaire item	Questionnaire item	Questionnaire item
Deprivation status	Indexes of multiple deprivation	Indexes of multiple deprivation	Indexes of multiple deprivation
Recent financial problems	Questionnaire item	Questionnaire item	Questionnaire item
Partner emotional abuse	Life events questionnaire	Not assessed	Not assessed
Parent with young children	Not assessed	Questionnaire item	Questionnaire item
<b><u>Biological factors</u></b>			
Obesity	BMI > 30 assessed at a research clinic	BMI > 30 assessed at a research clinic	BMI > 30 assessed at a research clinic
Asthma	Questionnaire item	Questionnaire item	Questionnaire item
<b><u>COVID-19 specific factors</u></b>			
Infection status	Questionnaire item	Questionnaire item	Questionnaire item
Isolation status	Questionnaire item	Questionnaire item	Not assessed
Living alone	Questionnaire item	Questionnaire item	Questionnaire item
No access to a garden	Questionnaire item	Questionnaire item	Questionnaire item
Health care worker	Questionnaire item	Questionnaire item	Not assessed
Key worker	Questionnaire item	Questionnaire item	Questionnaire item
<b><u>Baseline mental health measures</u></b>			
Depressive symptoms	Edinburgh postnatal depression scale	Short mood and feelings questionnaire	General health questionnaire - depression
Anxiety	Spielberger state-trait anxiety inventory	Generalised anxiety disorder assessment	General health questionnaire - anxiety
Mental wellbeing	Not assessed	Warwick-Edinburgh mental wellbeing scale	Not assessed

**Psychiatric or mental health factors**

Probable major depression (MDD)	Life events questionnaire	Clinical interview schedule - revised	Structured clinical interview for DSM-IV
Probable generalised anxiety disorder (GAD)	Life events questionnaire	Clinical interview schedule - revised	Not assessed
Psychosis like experiences	Not assessed	Psychosis like symptoms interview	Schizotypal personality questionnaire
Disordered eating	Life events questionnaire	Questionnaire items consistent with DSM-V frequency	Not assessed
Obsessive compulsive disorder traits (OCD)	Not assessed	Obsessive-compulsive inventory	Not assessed
Autistic traits	Not assessed	Social responsiveness scale	Not assessed
Personality disorder traits	Karolinska scales of personality	Standardised assessment of personality: abbreviated scale	Not assessed
History of alcohol misuse	Alcohol use disorders identification test	Alcohol use disorders identification test	Questionnaire item
Current smokers (tobacco)	Questionnaire items	Questionnaire items	Questionnaire items
Cognitive styles	Negative schemas questionnaire	Cognitive styles questionnaire	Brief resilience scale
Difficulties accessing mental health information	Not assessed	Public health questionnaire	Not assessed
Neuroticism	Not assessed	Big five factors of personality – neuroticism	Eysenck personality questionnaire – neuroticism
Self-harm history	Not assessed	Questionnaire items	Linkage to medical records
Depression polygenic risk score (PRS)	Constructed from a recent GWAS on depression	Constructed from a recent GWAS on depression	Constructed from a recent GWAS on depression

**Table 1.** Baseline mental health measures and factors assessed in ALSPAC and Generation Scotland.

	Depression standardised estimates (95% CIs), <i>P</i>			Anxiety standardised estimates (95% CIs), <i>P</i>		
	ALSPAC G0 (n=3579)	ALSPAC G1 (n=2872)	Gen Scot (n=4208)	ALSPAC G0 (n=3579)	ALSPAC G1 (n=2872)	Gen Scot (n=4208)
<b><u>Sociodemographic factors</u></b>						
Sex (female) (76% / 72% / 64%)*	0.28 (0.21, 0.34) <i>P</i> = 1.46 x 10 <sup>-19</sup>	0.22 (0.15, 0.29) <i>P</i> = 1.20 x 10 <sup>-9</sup>	0.27 (0.22, 0.32) <i>P</i> = 4.07 x 10 <sup>-22</sup>	0.26 (0.20, 0.32) <i>P</i> = 7.87 x 10 <sup>-17</sup>	0.40 (0.33, 0.48) <i>P</i> = 3.57 x 10 <sup>-23</sup>	0.18 (0.12, 0.23) <i>P</i> = 6.63 x 10 <sup>-10</sup>
Age (older ages) (scale variable)**	-0.02 (-0.03, -0.01) <i>P</i> = 2.08 x 10 <sup>-8</sup>	-0.01 (-0.07, 0.04) <i>P</i> = 0.643	-0.02 (-0.02, -0.02) <i>P</i> = 4.57 x 10 <sup>-46</sup>	-0.02 (-0.03, -0.02) <i>P</i> = 4.82 x 10 <sup>-12</sup>	0.00 (-0.06, 0.07) <i>P</i> = 0.945	-0.01 (-0.02, -0.01) <i>P</i> = 1.25 x 10 <sup>-30</sup>
Lower educational background (11% / 16% / 13%)	0.23 (0.12, 0.35) <i>P</i> = 0.00008	0.05 (-0.04, 0.15) <i>P</i> = 0.276	0.15 (0.06, 0.24) <i>P</i> = 0.001	0.14 (0.03, 0.25) <i>P</i> = 0.016	0.16 (0.06, 0.26) <i>P</i> = 0.002	0.09 (0.00, 0.18) <i>P</i> = 0.061
Higher income (scale variable)	-0.04 (-0.06, -0.03) <i>P</i> = 6.22 x 10 <sup>-8</sup>	-0.01 (-0.04, 0.01) <i>P</i> = 0.328	-0.10 (-0.13, -0.08) <i>P</i> = 5.14 x 10 <sup>-16</sup>	-0.01 (-0.03, 0.00) <i>P</i> = 0.052	-0.04 (-0.07, -0.01) <i>P</i> = 0.008	-0.07 (-0.09, -0.04) <i>P</i> = 5.46 x 10 <sup>-7</sup>
Worse deprivation status (scale variable)	0.07 (0.04, 0.10) <i>P</i> = 0.00002	0.01 (-0.01, 0.04) <i>P</i> = 0.319	0.06 (0.04, 0.09) <i>P</i> = 7.33 x 10 <sup>-7</sup>	0.05 (0.02, 0.08) <i>P</i> = 0.001	0.04 (0.01, 0.07) <i>P</i> = 0.005	0.04 (0.02, 0.06) <i>P</i> = 0.001
Financial problems (11% / 10% / 4%)	0.29 (0.15, 0.43) <i>P</i> = 0.00005	0.14 (0.03, 0.26) <i>P</i> = 0.015	0.38 (0.18, 0.58) <i>P</i> = 0.0002	0.20 (0.07, 0.32) <i>P</i> = 0.011	0.24 (0.12, 0.36) <i>P</i> = 0.0002	0.20 (0.00, 0.39) <i>P</i> = 0.049
Partner emotional abuse (8% / Na / Na)	0.36 (0.18, 0.53) <i>P</i> = 0.00005	Not assessed	Not assessed	0.29 (0.13, 0.46) <i>P</i> = 0.001	Not assessed	Not assessed
Parent with young children (Na / 11% / 11%)	Not assessed	0.03 (-0.07, 0.13) <i>P</i> = 0.570	-0.03 (-0.14, 0.08) <i>P</i> = 0.617	Not assessed	0.19 (0.08, 0.30) <i>P</i> = 0.001	0.05 (-0.05, 0.16) <i>P</i> = 0.353
<b><u>Biological factors</u></b>						
Obesity (18 % / 14% / 20%)	0.22 (0.12, 0.32) <i>P</i> = 0.00001	0.18 (0.06, 0.31) <i>P</i> = 0.004	0.32 (0.24, 0.40) <i>P</i> = 1.09 x 10 <sup>-14</sup>	0.14 (0.04, 0.25) <i>P</i> = 0.005	0.15 (0.03, 0.27) <i>P</i> = 0.012	0.10 (0.02, 0.18) <i>P</i> = 0.010
Asthma (16% / 10% / 10%)	0.07 (-0.02, 0.16) <i>P</i> = 0.127	0.08 (-0.04, 0.20) <i>P</i> = 0.196	0.18 (0.07, 0.28) <i>P</i> = 0.001	0.07 (-0.02, 0.16) <i>P</i> = 0.14	0.21 (0.07, 0.35) <i>P</i> = 0.003	0.12 (0.02, 0.22) <i>P</i> = 0.016
<b><u>COVID-19 specific factors</u></b>						
COVID-19 infection (12% / 16% / 8%)	0.18 (0.07, 0.28) <i>P</i> = 0.001	0.09 (0.00, 0.17) <i>P</i> = 0.045	0.17 (0.05, 0.29) <i>P</i> = 0.004	0.16 (0.06, 0.27) <i>P</i> = 0.003	0.08 (-0.02, 0.17) <i>P</i> = 0.112	0.10 (-0.02, 0.21) <i>P</i> = 0.101
Self-isolation (19% / 25% / Na)	0.20 (0.11, 0.29) <i>P</i> = 6.64 x 10 <sup>-6</sup>	0.15 (0.08, 0.22) <i>P</i> = 0.00004	Not assessed	0.13 (0.04, 0.27) <i>P</i> = 0.003	0.17 (0.09, 0.25) <i>P</i> = 0.00003	Not assessed

Living alone (8% / 6% / 16%)	0.45 (0.30, 0.59) $P = 4.80 \times 10^{-9}$	0.20 (0.06, 0.34) $P = 0.005$	0.19 (0.11, 0.27) $P = 4.47 \times 10^{-6}$	-0.06 (-0.19, 0.07) $P = 0.372$	0.06 (-0.08, 0.21) $P = 0.392$	-0.03 (-0.11, 0.06) $P = 0.539$
No access to a garden (2% / 18% / 8%)	0.47 (0.09, 0.85) $P = 0.016$	0.16 (0.07, 0.24) $P = 0.0002$	0.24 (0.12, 0.37) $P = 0.0001$	-0.07 (-0.35, 0.21) $P = 0.62$	0.05 (-0.04, 0.14) $P = 0.235$	0.16 (0.04, 0.28) $P = 0.007$
Health care worker (11% / 12% / NA)	0.01 (-0.09, 0.10) $P = 0.901$	-0.02 (-0.12, 0.08) $P = 0.683$	Not assessed	-0.03 (-0.13, 0.07) $P = 0.597$	0.02 (-0.08, 0.13) $P = 0.652$	Not assessed
Key worker (32% / 39% / 22%)	0.04 (-0.03, 0.11) $P = 0.214$	-0.09 (-0.15, -0.02) $P = 0.008$	-0.05 (-0.13, 0.02) $P = 0.178$	0.03 (-0.04, 0.10) $P = 0.441$	0.02 (-0.05, 0.09) $P = 0.631$	0.04 (-0.03, 0.12) $P = 0.266$
<b><u>Psychiatric or mental health factors</u></b>						
Probable MDD (8% / 14% / 14%)	0.38 (0.22, 0.54) $P = 2.29 \times 10^{-6}$	0.31 (0.20, 0.42) $P = 3.18 \times 10^{-8}$	0.39 (0.29, 0.49) $P = 1.84 \times 10^{-13}$	0.26 (0.11, 0.40) $P = 0.0005$	0.49 (0.39, 0.62) $P = 1.33 \times 10^{-16}$	0.27 (0.17, 0.38) $P = 7.03 \times 10^{-7}$
Probable GAD (7% / 13% / Na)	0.26 (0.11, 0.42) $P = 0.001$	0.14 (0.03, 0.25) $P = 0.010$	Not assessed	0.25 (0.09, 0.40) $P = 0.002$	0.50 (0.39, 0.62) $P = 2.72 \times 10^{-17}$	Not assessed
Psychosis like experiences (Na / 15% / scale)	Not assessed	0.17 (0.07, 0.27) $P = 0.001$	0.15 (0.11, 0.19) $P = 3.72 \times 10^{-14}$	Not assessed	0.25 (0.15, 0.36) $P = 4.74 \times 10^{-6}$	0.12 (0.08, 0.16) $P = 9.59 \times 10^{-9}$
Disordered eating (3% / 9% / Na)	0.09 (-0.14, 0.32) $P = 0.689$	0.21 (0.09, 0.34) $P = 0.0005$	Not assessed	0.08 (-0.16, 0.32) $P = 0.510$	0.26 (0.12, 0.40) $P = 0.0002$	Not assessed
OCD traits (scale variable)	Not assessed	0.05 (0.01, 0.09) $P = 0.027$	Not assessed	Not assessed	0.15 (0.11, 0.19) $P = 8.28 \times 10^{-13}$	Not assessed
Autistic traits (Na / 7% / Na)	Not assessed	0.19 (0.05, 0.34) $P = 0.008$	Not assessed	Not assessed	0.35 (0.20, 0.51) $P = 5.18 \times 10^{-6}$	Not assessed
Personality disorder traits (11% / 11% / Na)	0.32 (0.19, 0.45) $P = 1.67 \times 10^{-6}$	0.09 (0.04, 0.23) $P = 0.169$	Not assessed	0.15 (0.02, 0.27) $P = 0.021$	0.27 (0.14, 0.40) $P = 0.00008$	Not assessed
History of alcohol misuse (17% / 9% / 16%)	0.04 (-0.05, 0.13) $P = 0.367$	0.13 (0.01, 0.25) $P = 0.040$	0.02 (-0.06, 0.10) $P = 0.598$	0.09 (0.00, 0.18) $P = 0.047$	0.20 (0.07, 0.33) $P = 0.003$	-0.02 (-0.10, 0.06) $P = 0.569$
Current smokers (tobacco) (29% / 12% / 10%)	0.18 (0.10, 0.25) $P = 7.58 \times 10^{-6}$	0.02 (-0.09, 0.13) $P = 0.690$	0.30 (0.19, 0.41) $P = 1.23 \times 10^{-7}$	0.12 (0.05, 0.20) $P = 0.001$	0.10 (-0.01, 0.21) $P = 0.085$	0.18 (0.08, 0.29) $P = 0.001$
Negative cognitive styles (scale variable)	0.21 (0.16, 0.25) $P = 1.07 \times 10^{-18}$	0.09 (0.05, 0.13) $P = 0.00004$	0.22 (0.19, 0.26) $P = 2.97 \times 10^{-32}$	0.16 (0.12, 0.20) $P = 3.07 \times 10^{-14}$	0.07 (0.02, 0.12) $P = 0.003$	0.19 (0.15, 0.22) $P = 5.39 \times 10^{-21}$

Difficulties accessing mental health info (Na / 23% / Na)	Not assessed	0.12 (0.03, 0.20) <i>P</i> = 0.009	Not assessed	Not assessed	0.28 (0.19, 0.36) <i>P</i> = 1.93 x 10 <sup>-9</sup>	Not assessed
Higher neuroticism (scale variable)	Not assessed	0.04 (0.01, 0.09) <i>P</i> = 0.015	0.22 (0.19, 0.26) <i>P</i> = 3.00 x 10 <sup>-42</sup>	Not assessed	0.11 (0.07, 0.15) <i>P</i> = 7.33 x 10 <sup>-7</sup>	0.21 (0.18, 0.25) <i>P</i> = 1.97 x 10 <sup>-31</sup>
Self-harm history (Na / 24% / 2%)	Not assessed	0.15 (0.06, 0.23) <i>P</i> = 0.001	0.55 (0.22, 0.88) <i>P</i> = 0.001	Not assessed	0.19 (0.09, 0.28) <i>P</i> = 0.0002	0.58 (0.28, 0.88) <i>P</i> = 1.97 x 10 <sup>-8</sup>
Depression PRS*** (scale variable)	0.09 (0.05, 0.13) <i>P</i> = 0.00002 (n=1906)	0.03 (-0.02, 0.07) <i>P</i> = 0.224 (n=1592)	0.05 (0.02, 0.08) <i>P</i> = 0.0002 (n=3849)	0.09 (0.05, 0.14) <i>P</i> = 0.00004 (n=2071)	0.00 (-0.05, 0.05) <i>P</i> = 0.993 (n=1329)	0.06 (0.03, 0.09) <i>P</i> = 0.00002 (n=3832)

**Table 2.** Associations between baseline risk factors and depression and anxiety using the imputed samples. Results are standardised estimates for depression and anxiety, adjusted for prior depression or anxiety, sex, age and when the COVID-19 questionnaire was completed. \*Indicates the % of individuals with caseness for ALSPAC-G0 / ALSPAC-G1 / GS respectively. \*\*Indicates a continuous scale was used so no proportions are given. \*\*\*Indicates this was on complete case analysis only. MDD: major depressive disorder; GAD: generalised anxiety disorder; OCD: obsessive compulsive disorder; PRS: polygenic risk score.

**Figure 1.** Mental health during COVID-19 in ALSPAC-G0, ALSPAC-G1 and Generation Scotland (GS). Figure 1A (top left) shows probable depression, probable generalised anxiety disorder (GAD) and lower wellbeing by each cohort. Figure 1B (top right) shows probable depression by age groups assessed using the SMFQ in ALSPAC and PHQ-9 in GS. Figure 1C (bottom left) shows probable GAD by age groups assessed by the GAD-7. Figure 1D shows lower wellbeing by age groups assessed by the SWEMWBS. Note, ALSPAC-G1 (n=2812) were categorised as 18-40, even though the max age of this cohort is 29 years. Age in ALSPAC-G0 was split by the following: Age 40-49 (n=89), Age 50-59 (n=2105), Age 60-69 (n=1455) and Age 70+ (n=71). In GS, Age was split by the following: Age 18-40 (n=356), Age 40-49 (n=534), Age 50-59 (n=964), Age 60-69 (n=1526) and Age 70+ (n=853).

**Figure 2.** Changes in mental health across baseline (pre-pandemic) to COVID-19 in ALSPAC-G1. Figure 2A (top left) shows changes in probable depression as assessed by the SMFQ. Figure 2B (top right) shows changes in probable GAD assessed by the GAD-7 at age 22 and CISR GAD at ages 18 and 24. Figure 2C (bottom left) shows changes in lower wellbeing assessed by the SWEMWBS.

**Figure 3.** Item level changes in mental health between the most recent baseline and COVID-19 in ALSPAC-G1. Figure 3A (top left) shows how items of the SMFQ (depression) vary from the most recent baseline (Age 26) to COVID-19. Figure 3B (top right) shows how items of the GAD-7 (anxiety) vary from the most recent baseline (Age 22) to COVID-19. Figure 3C (bottom left) shows high items from the SWEMWBS (mental wellbeing) vary from the most recent baseline (Age 24) to COVID-19.

**Figure 4.** Associations between baseline and COVID-19 factors and depression during COVID-19, adjusted for baseline depression, sex, age and when the COVID-19 questionnaire was completed, using imputed data. Estimates refer to a standard deviation increase in depression, over and above depression at baseline. Figure 4A (top left) shows associations between baseline sociodemographic factors and depression during COVID-19. Figure 4B (top right) shows associations between baseline physical health and COVID-19 specific factors and depression during COVID-19. Figure 4C (bottom left) and Figure 4D (bottom right) shows associations between baseline mental health factors and depression during COVID-19.

**Figure 5.** Associations between baseline and COVID-19 factors and anxiety during COVID-19, adjusted for baseline anxiety, sex, age and when the COVID-19 questionnaire was completed, using imputed data. Estimates refer to a standard deviation increase in anxiety, over and above anxiety at baseline. Figure 4A (top left) shows associations between baseline sociodemographic factors and anxiety during COVID-19. Figure 4B (top right) shows associations between baseline physical health and COVID-19 specific factors and anxiety during COVID-19. Figure 4C (bottom left) and Figure 4D (bottom right) shows associations between baseline mental health factors and anxiety during COVID-19.







Figure 1.








Figure 2.






Figure 3.







Figure 4.






Figure 5.